Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. (Q36613519)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17019434%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

review article

1 reference

title

Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17019434%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17019434%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Brigitte M Pützer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17019434%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17019434%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Oncology

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17019434%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17019434%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17019434%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

564-574

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17019434%20AND%20SRC:MED&resulttype=core&format=json

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Beyond Herceptin and Gleevec

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Current approaches and perspectives in the therapy of medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The RET proto-oncogene: a potential target for molecular cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

RET tyrosine kinase signaling in development and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The GDNF family: signalling, biological functions and therapeutic value

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The GDNF family ligands and receptors - implications for neural development

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Renal agenesis and the absence of enteric neurons in mice lacking GDNF

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The GDNF/RET signaling pathway and human diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The RET receptor: function in development and dysfunction in congenital malformation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

MEN2A-RET-induced cellular transformation by activation of STAT3

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

RAS and RHO GTPases in G1-phase cell-cycle regulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0610

1 reference

7 January 2021

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Surgical treatment of medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The specificities of protein kinase inhibitors: an update

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

ZD6474--clinical experience to date

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Receptor tyrosine kinases as targets for anticancer therapeutics.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

17-AAG: mechanisms of antitumour activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Evolving strategies for targeted cancer therapy--past, present, and future

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0610

7 January 2021

Identifiers

DOI

10.1038/NCPONC0610

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17019434%20AND%20SRC:MED&resulttype=core&format=json

release_rdg4abo6hrcsxachsmzccpr33i

20 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rdg4abo6hrcsxachsmzccpr33i

24 November 2022

mapped directly with Wikidata item

1 reference